Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series

Nishan Tchekmedyian, Raja Mudad, Fernando F. Blanco, Victoria M. Raymond, Jordan Garst, Mark G. Erlander, Eric Haura, David Berz

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Targetable, somatic EGFR mutations are highly prevalent in patients with non-small cell lung cancer (NSCLC), making them eligible for tyrosine kinase inhibitor (TKI) therapy. Circulating tumor DNA (ctDNA), isolated from blood or urine, has been demonstrated to reliably identify somatic tumor associated EGFR mutations, specifically in patients with inconclusive biopsy. When conventional imaging modalities are inconclusive, quantitative assessment of systemic ctDNA burden has the potential to assess therapeutic response. We report on the clinical use of non-invasive, urinary ctDNA liquid biopsies for the ultrasensitive detection and longitudinal monitoring of ctDNA EGFR systemic mutation burden in five patients with NSCLC treated with EGFR TKIs. Urinary ctDNA-based quantitative assessment of systemic EGFR mutant allele burden is a non-invasive molecular diagnostic testing modality that has the potential to be utilized as an ancillary tool to assess disease burden and response to therapy.

Original languageEnglish (US)
Pages (from-to)22-28
Number of pages7
JournalLung Cancer
Volume108
DOIs
StatePublished - Jun 1 2017

Fingerprint

Urine
Mutation
DNA
Neoplasms
Non-Small Cell Lung Carcinoma
Molecular Diagnostic Techniques
Biopsy
Tumor Burden
Protein-Tyrosine Kinases
Therapeutics
Alleles

Keywords

  • Circulating tumor DNA
  • EGFR
  • Longitudinal monitoring
  • Non-small cell lung cancer
  • Systemic mutation burden
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs : A case series. / Tchekmedyian, Nishan; Mudad, Raja; Blanco, Fernando F.; Raymond, Victoria M.; Garst, Jordan; Erlander, Mark G.; Haura, Eric; Berz, David.

In: Lung Cancer, Vol. 108, 01.06.2017, p. 22-28.

Research output: Contribution to journalArticle

Tchekmedyian, Nishan ; Mudad, Raja ; Blanco, Fernando F. ; Raymond, Victoria M. ; Garst, Jordan ; Erlander, Mark G. ; Haura, Eric ; Berz, David. / Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs : A case series. In: Lung Cancer. 2017 ; Vol. 108. pp. 22-28.
@article{28e39acd706a48379ed47071652c0146,
title = "Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series",
abstract = "Targetable, somatic EGFR mutations are highly prevalent in patients with non-small cell lung cancer (NSCLC), making them eligible for tyrosine kinase inhibitor (TKI) therapy. Circulating tumor DNA (ctDNA), isolated from blood or urine, has been demonstrated to reliably identify somatic tumor associated EGFR mutations, specifically in patients with inconclusive biopsy. When conventional imaging modalities are inconclusive, quantitative assessment of systemic ctDNA burden has the potential to assess therapeutic response. We report on the clinical use of non-invasive, urinary ctDNA liquid biopsies for the ultrasensitive detection and longitudinal monitoring of ctDNA EGFR systemic mutation burden in five patients with NSCLC treated with EGFR TKIs. Urinary ctDNA-based quantitative assessment of systemic EGFR mutant allele burden is a non-invasive molecular diagnostic testing modality that has the potential to be utilized as an ancillary tool to assess disease burden and response to therapy.",
keywords = "Circulating tumor DNA, EGFR, Longitudinal monitoring, Non-small cell lung cancer, Systemic mutation burden, Tyrosine kinase inhibitors",
author = "Nishan Tchekmedyian and Raja Mudad and Blanco, {Fernando F.} and Raymond, {Victoria M.} and Jordan Garst and Erlander, {Mark G.} and Eric Haura and David Berz",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.lungcan.2017.02.010",
language = "English (US)",
volume = "108",
pages = "22--28",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs

T2 - A case series

AU - Tchekmedyian, Nishan

AU - Mudad, Raja

AU - Blanco, Fernando F.

AU - Raymond, Victoria M.

AU - Garst, Jordan

AU - Erlander, Mark G.

AU - Haura, Eric

AU - Berz, David

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Targetable, somatic EGFR mutations are highly prevalent in patients with non-small cell lung cancer (NSCLC), making them eligible for tyrosine kinase inhibitor (TKI) therapy. Circulating tumor DNA (ctDNA), isolated from blood or urine, has been demonstrated to reliably identify somatic tumor associated EGFR mutations, specifically in patients with inconclusive biopsy. When conventional imaging modalities are inconclusive, quantitative assessment of systemic ctDNA burden has the potential to assess therapeutic response. We report on the clinical use of non-invasive, urinary ctDNA liquid biopsies for the ultrasensitive detection and longitudinal monitoring of ctDNA EGFR systemic mutation burden in five patients with NSCLC treated with EGFR TKIs. Urinary ctDNA-based quantitative assessment of systemic EGFR mutant allele burden is a non-invasive molecular diagnostic testing modality that has the potential to be utilized as an ancillary tool to assess disease burden and response to therapy.

AB - Targetable, somatic EGFR mutations are highly prevalent in patients with non-small cell lung cancer (NSCLC), making them eligible for tyrosine kinase inhibitor (TKI) therapy. Circulating tumor DNA (ctDNA), isolated from blood or urine, has been demonstrated to reliably identify somatic tumor associated EGFR mutations, specifically in patients with inconclusive biopsy. When conventional imaging modalities are inconclusive, quantitative assessment of systemic ctDNA burden has the potential to assess therapeutic response. We report on the clinical use of non-invasive, urinary ctDNA liquid biopsies for the ultrasensitive detection and longitudinal monitoring of ctDNA EGFR systemic mutation burden in five patients with NSCLC treated with EGFR TKIs. Urinary ctDNA-based quantitative assessment of systemic EGFR mutant allele burden is a non-invasive molecular diagnostic testing modality that has the potential to be utilized as an ancillary tool to assess disease burden and response to therapy.

KW - Circulating tumor DNA

KW - EGFR

KW - Longitudinal monitoring

KW - Non-small cell lung cancer

KW - Systemic mutation burden

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85014466305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014466305&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2017.02.010

DO - 10.1016/j.lungcan.2017.02.010

M3 - Article

C2 - 28625639

AN - SCOPUS:85014466305

VL - 108

SP - 22

EP - 28

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -